Related Experiment Videos
Short-term effects of celiprolol on blood pressure and left ventricular performance in hypertensive cardiomyopathy
F J Rodríguez Rodrigo1, I Ruiz, J G Lorenzo
1Cardiology Department, Carlos III Institute, Madrid, Spain.
Insights
Celiprolol effectively lowers blood pressure in hypertensive patients by reducing systemic vascular resistance. This beta-blocker also improves left ventricular diastolic function without negatively impacting cardiac output or ejection fraction.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Celiprolol is a novel beta-1 blocker with partial beta-2 agonistic properties.
- Hypertension management often requires agents that improve cardiac function.
- Left ventricular hypertrophy is a common comorbidity in hypertensive patients.
Purpose of the Study:
- To evaluate the antihypertensive efficacy of Celiprolol.
- To assess the short-term effects of Celiprolol on systemic vascular resistance (SVR), cardiac output (CO), left ventricular ejection fraction (LVEF), and left ventricular diastolic performance (LVDP).
Main Methods:
- Open-label study involving 20 hypertensive patients with left ventricular hypertrophy.
- Daily administration of 400 mg Celiprolol for 4 weeks.
- Doppler echocardiography was utilized to assess hemodynamic parameters.
Main Results:
- Celiprolol significantly reduced systolic and diastolic blood pressure.
- A significant decrease in systemic vascular resistance was observed.
- Left ventricular diastolic function improved, evidenced by reduced early diastolic deceleration time and isovolumetric relaxation time.
- Heart rate, cardiac output, and left ventricular ejection fraction showed non-significant changes.
Conclusions:
- Celiprolol demonstrates significant antihypertensive efficacy.
- The drug favorably impacts systemic vascular resistance and left ventricular diastolic function.
- Celiprolol is a potential therapeutic option for hypertensive patients, particularly those with left ventricular hypertrophy.
Abstract:
Celiprolol (C) is a new selective beta 1-blocker with partial beta 2-agonistic activity. The purpose of this study was to explore its antihypertensive efficacy and its short-term effect on systemic vascular resistances (SVR), cardiac output (CO), left ventricular ejection fraction (LVEF), and left ventricular diastolic performance (LVDP). The Doppler technique was used. In an open-label study, 20 hypertensive patients (15 males, 5 females, age range of 29-68 years) with left ventricular hypertrophy detected by echography were daily treated with 400 mg of C in a single dose, for a period of 4 weeks. C reduced significantly the systolic blood pressure (SBP) and the diastolic blood pressure (DBP) (158 +/- 12 vs. 142 +/- 11 mm Hg, p < 0.05 and 101 +/- 6 vs. 87 +/- 4 mm Hg, p < 0.001, respectively) with a decrease in heart rate (74 +/- 12 vs. 67 +/- 8 beats/min, p = NS). The SVR decreased significantly (2,050 +/- 22 vs. 1,495 +/- 23 dyn/s/cm5, p < 0.001) with a slight but not significant increase in the CO (4.5 +/- 0.69 vs. 5.11 +/- 0.82 L/min). The LVEF did not decrease significantly (58 +/- 5 vs. 56.9 +/- 6%, p = NS) while the LVDP was modified favorably, significantly reducing the early diastolic deceleration time (EDDT) (199 +/- 61 vs. 132 +/- 80 ms, p < 0.01) and reducing the isovolumetric relaxation time (IVRT) (167 +/- 16 vs. 117 +/- 23 ms, p < 0.001).(ABSTRACT TRUNCATED AT 250 WORDS)